376 related articles for article (PubMed ID: 37344763)
1. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery.
Arango C; Fagiolini A; Gorwood P; Kane JM; Diaz-Mendoza S; Sahota N; Correll CU
BMC Psychiatry; 2023 Jun; 23(1):453. PubMed ID: 37344763
[TBL] [Abstract][Full Text] [Related]
2. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery.
Arango C; Fagiolini A; Gorwood P; Kane JM; Diaz-Mendoza S; Sahota N; Correll CU
Res Sq; 2023 Mar; ():. PubMed ID: 36945577
[TBL] [Abstract][Full Text] [Related]
3. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
Stevens GL; Dawson G; Zummo J
Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of long-acting injectable
Vita G; Tavella A; Ostuzzi G; Tedeschi F; De Prisco M; Segarra R; Solmi M; Barbui C; Correll CU
Ther Adv Psychopharmacol; 2024; 14():20451253241257062. PubMed ID: 38831918
[TBL] [Abstract][Full Text] [Related]
6. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
Kane JM; McEvoy JP; Correll CU; Llorca PM
CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
[TBL] [Abstract][Full Text] [Related]
7. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
Kishimoto T; Hagi K; Kurokawa S; Kane JM; Correll CU
Lancet Psychiatry; 2021 May; 8(5):387-404. PubMed ID: 33862018
[TBL] [Abstract][Full Text] [Related]
8. Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN).
Yang KC; Liao YT; Yang YK; Lin SK; Liang CS; Bai YM
CNS Drugs; 2021 Aug; 35(8):893-905. PubMed ID: 34312788
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
Fang SC; Huang CY; Shao YJ
J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35649156
[No Abstract] [Full Text] [Related]
10. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
Lin CH; Chen FC; Chan HY; Hsu CC
Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis.
Lian L; Kim DD; Procyshyn RM; Fredrikson DH; Cázares D; Honer WG; Barr AM
Early Interv Psychiatry; 2022 Jun; 16(6):589-599. PubMed ID: 34263540
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging long-acting antipsychotics for the treatment of schizophrenia.
de Filippis R; De Fazio P; Gaetano R; Steardo L; Cedro C; Bruno A; Zoccali RA; Muscatello MRA
Expert Opin Drug Saf; 2021 Jul; 20(7):771-790. PubMed ID: 33775184
[No Abstract] [Full Text] [Related]
13. Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India.
Gundugurti PR; Nagpal R; Sheth A; Narang P; Gawande S; Singh V
Asian J Psychiatr; 2017 Dec; 30():88-93. PubMed ID: 28843143
[TBL] [Abstract][Full Text] [Related]
14. Long-acting injectable antipsychotics: evidence of effectiveness and use.
Manchanda R; Chue P; Malla A; Tibbo P; Roy MA; Williams R; Iyer S; Lutgens D; Banks N
Can J Psychiatry; 2013 May; 58(5 Suppl 1):5S-13S. PubMed ID: 23945067
[TBL] [Abstract][Full Text] [Related]
15. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.
Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
Can J Psychiatry; 2013 May; 58(5 Suppl 1):23S-9S. PubMed ID: 23945064
[TBL] [Abstract][Full Text] [Related]
16. Rethinking the role of long-acting atypical antipsychotics in the community setting.
Altamura AC; Aguglia E; Bassi M; Bogetto F; Cappellari L; De Giorgi S; Fagiolini A; Ferrannini L; Girardi P
Int Clin Psychopharmacol; 2012 Nov; 27(6):336-49. PubMed ID: 22859065
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
18. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
Lin CH; Chan HY; Hsu CC; Chen FC
J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
[TBL] [Abstract][Full Text] [Related]
19. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).
Brugnoli R; Rapinesi C; Kotzalidis GD; Marcellusi A; Mennini FS; De Filippis S; Carrus D; Ballerini A; Francomano A; Ducci G; Del Casale A; Girardi P
Riv Psichiatr; 2016; 51(2):47-59. PubMed ID: 27183509
[TBL] [Abstract][Full Text] [Related]
20. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder.
Abdel-Baki A; Thibault D; Medrano S; Stip E; Ladouceur M; Tahir R; Potvin S
Early Interv Psychiatry; 2020 Feb; 14(1):69-79. PubMed ID: 31125513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
